Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Methods for cost control focus on rigorous allocation and review cycles, enabling proactive adjustments to keep spending in check.
23,153 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Antero Midstream logged 271% total returns over three years and closed a $1.1 billion Marcellus asset deal. The 2026 ...
SoFi stock has spent months sliding as optimism cooled and risks stacked up. This in-depth guide explains what's behi...
Investors eye a steady $5,000 per month in dividends as a way to replace part of a paycheck. This report breaks down ...
Chattanooga launches a novel unit-level PILOT designed to mix affordable and market-rate apartments. The plan ties pe...
When policymakers hint at rate moves, investors scramble to reprice risk. This guide breaks down how an evolving inte...
Despite regulatory progress and new market access, XRP has struggled to break out in 2026. This piece analyzes whethe...
SpaceX's IPO spark has investors buzzing, but Warren Buffett would never chase hype without a moat and predictable ca...
A daring forecast from Goldman Sachs imagines SpaceX turning into a multi-hundred-billion-dollar revenue machine by 2...
Savara investors should stay focused on how insider moves and regulatory timelines interact with a growing biotech st...
Asana has fallen from pandemic highs, but buying the dip isn’t a guaranteed win. This guide explains the risks, what ...
June inflation slowed, but the path for interest rates is far from clear. This piece unpacks these four words, explai...